Peptide

Ra Pharmaceuticals Presents Pre-Clinical Data for Zilucoplan XR at the 6th Annual Peptides Congress

Retrieved on: 
Wednesday, April 24, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, Pharmacology, Health sciences, Pharmaceutical sciences, Biodegradable plastics, Synthetic fibers, Copolymers, PLGA, Pharmacokinetics, Peptide, Modified-release dosage

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today presented pre-clinical data for an extended release (XR) formulation of zilucoplan at the 6th Annual Peptides Congress, taking place April 24-25, 2019, in London, UK.

Key Points: 
  • Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today presented pre-clinical data for an extended release (XR) formulation of zilucoplan at the 6th Annual Peptides Congress, taking place April 24-25, 2019, in London, UK.
  • This XR formulation of zilucoplan employs poly(D,L-lactic-co-glycolic acid) (PLGA) technology, an established delivery platform for sustained release of peptides.
  • The PLGA XR formulation of zilucoplan is designed to produce uniform particles with homogenous distribution of zilucoplan and a predictable release profile.
  • The presentation from the 6th Annual Peptides Congress can be accessed by visiting the Presentations and Publications section of the Ra Pharma website: www.rapharma.com .

The Perfect Eye Serum That Helps With Under Eye Puffiness and Redness by DermaSet

Retrieved on: 
Tuesday, April 23, 2019
Cytokinins, Furans, Kinetin, Hordeum, Peptide

HOLLYWOOD, Fla., April 22, 2019 /PRNewswire/ -- DermaSet Skin Care is pleased to announce the launch of DermaSet Premium Eye Serum Complex with kinetin and triple peptide compound.

Key Points: 
  • HOLLYWOOD, Fla., April 22, 2019 /PRNewswire/ -- DermaSet Skin Care is pleased to announce the launch of DermaSet Premium Eye Serum Complex with kinetin and triple peptide compound.
  • To assure the exceptional results, DermaSet Premium Eye Serum has clinically proven ingredients such as kinetin, pentapeptide-18, arnica extract, acetyl hexapeptide-8, acetyl octapeptide-3, hyalronic acid, and hordeum distichon (known as barley extract).
  • "We are pleased to add this new eye serum to our anti-aging products," says Marie Urina, CEO at DermaSet.
  • In addition to their new eye serum, the company has several products in the pipeline that help with aging process.

Swedish Biomimetics 3000 Invents Continuous Peptide Manufacturing Process μLOT®

Retrieved on: 
Thursday, March 28, 2019
Health, Biotechnology, Pharmaceutical, Manufacturing, Chemicals, Plastics, Research, Science, Branches of biology, Immunology, Immune system, Glycoproteins, Peptide, Biology, Antibody, Natural sciences

LOT is an entirely new approach to manufacturing therapeutic peptides, which promises to completely replace traditional large-scale batch manufacturing.

Key Points: 
  • LOT is an entirely new approach to manufacturing therapeutic peptides, which promises to completely replace traditional large-scale batch manufacturing.
  • The LOT technology provides continuous manufacturing of peptides enabling in-line process analytical technologies (PAT) throughout the process, providing an unprecedented level of quality, control and a significant cost reduction.
  • Jens Burkinsky, CTO of SB3000 commented, We believe that the LOT process will speed up development, reduce cost and enable the synthesis of drugs currently not economically or technically possible to produce.
  • We are developing the technology to cover the remaining market by including novel peptide designs such as lipid- and antibody-conjugations.

Novel Technologies for Delivery of Proteins, Antibodies and Nucleic Acids, 2019-2030

Retrieved on: 
Tuesday, March 26, 2019
Life sciences, Biology, Articles, Biotechnology, Immune system, Immunology, Glycoproteins, Antibody, Biopharmaceutical, Peptide

It offers a high-level view on the current state of the market for novel technologies for delivery of proteins, antibodies and nucleic acids, in the short-mid term and long term.

Key Points: 
  • It offers a high-level view on the current state of the market for novel technologies for delivery of proteins, antibodies and nucleic acids, in the short-mid term and long term.
  • Chapter 4 presents a list of novel technologies designed for the delivery of biotherapeutics.
  • Chapter 10 features a comprehensive market forecast analysis, highlighting the likely growth of novel technologies for delivery of biologics market till the year 2030.
  • Currently, over 80 technologies are available / being developed for the delivery of a variety of biotherapeutics, including proteins, peptides, antibodies and nucleic acids.

Global Customized Peptide Synthesis Market Report 2019: Analysis by Product, Application, Technology, End-user and Geography - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 26, 2019
Research, Science, Chemistry, Natural sciences, Peptides, Physical sciences, Chemical synthesis, Biochemistry, Peptide synthesis, Peptide, Synthesis

The customized peptide synthesis market is projected to generate a revenue of $390 million by 2024.

Key Points: 
  • The customized peptide synthesis market is projected to generate a revenue of $390 million by 2024.
  • There are two main types of products available in the customized peptide synthesis market: reagents and equipment.
  • New research findings would give the customized peptide synthesis market players a great opportunity to discover new drugs derived from peptides.
  • Such significant discoveries based on intensive research are projected to help in the growth of the customized peptide synthesis market in Asia-Pacific (APAC).

IMV and Centre de Recherche du CHU de Québec-Université Laval Collaboration Awarded a CQDM Grant to Develop First-in-Class Dual Target T Cell Therapy in Bladder Cancer Based on IMV’s DPX Technology

Retrieved on: 
Monday, March 18, 2019
Health, Clinical trials, Oncology, Pharmaceutical, Research, Science, Immunology, Peptide, Mage, Immunogenicity

The work will target immunogenic peptides identified by Dr Fradets team from the MAGE protein family member A9 (MAGE-A9).

Key Points: 
  • The work will target immunogenic peptides identified by Dr Fradets team from the MAGE protein family member A9 (MAGE-A9).
  • The collaborators will combine these peptides with IMVs proprietary DPX technology to develop a first-in-class dual target T cell therapy (DPX-SurMAGE).
  • This project contributes to position the Centre de recherche du CHU de Qubec-Universit Laval as a leader in medical innovation.
  • As part of the collaboration agreement, IMV holds an exclusive option to in-license intellectual property related to the program.

Global Oral Proteins & Peptides Market Analysis, Trends, Size, and Forecasts up to 2024 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 15, 2019
Health, Pharmaceutical, Peptide, Forecasting

The report on the global oral proteins and peptides market provides qualitative and quantitative analysis for the period from 2016 to 2024.

Key Points: 
  • The report on the global oral proteins and peptides market provides qualitative and quantitative analysis for the period from 2016 to 2024.
  • The report on oral proteins and peptides market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global oral proteins and peptides market over the period of 2016 to 2024.
  • Comprehensive analysis of the global as well as regional markets of the oral proteins and peptides market.
  • Complete coverage of all the segments in the oral proteins and peptides market to analyze the trends, developments in the global market and forecast of market size up to 2024.

Oral Proteins & Peptides: Worldwide Market to Exhibit a CAGR of 12.6% during 2018-2024 - Analysis on Key Opportunities

Retrieved on: 
Friday, March 15, 2019
Peptide, Forecasting

DUBLIN, March 15, 2019 /PRNewswire/ -- The "Oral Proteins and Peptides Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 15, 2019 /PRNewswire/ -- The "Oral Proteins and Peptides Market: Global Industry Analysis, Trends, Market Size, and Forecasts up to 2024" report has been added to ResearchAndMarkets.com's offering.
  • The report predicts the global oral proteins and peptides market to grow with a CAGR of 12.6% over the forecast period from 2018-2024.
  • The report on the global oral proteins and peptides market provides qualitative and quantitative analysis for the period from 2016 to 2024.
  • The report on oral proteins and peptides market is a comprehensive study and presentation of drivers, restraints, opportunities, demand factors, market size, forecasts, and trends in the global oral proteins and peptides market over the period of 2016 to 2024.

Global Collagen Peptides Market Report 2019 - ResearchAndMarkets.com

Retrieved on: 
Friday, February 15, 2019
Manufacturing, Chemicals, Plastics, Structural proteins, Chemical substances, Branches of biology, Excipients, Gelatin, Gels, Skin care, Collagen, Peptide, Nutrition

The "Global Collagen Peptides Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Collagen Peptides Market Analysis 2019" report has been added to ResearchAndMarkets.com's offering.
  • The Global Collagen Peptides market is expected to reach $1,950.35 million by 2026 growing at a CAGR of 13.2% during 2018 to 2026.
  • Collagen peptides are a cold-soluble, simply digestible and extremely bioactive form of collagen.
  • These are small bioactive peptides extracted by enzymatically hydrolysis of collagen, or the breaking down of the molecular bonds between individual collagen strands to peptides.

Global Cardiovascular Drug Delivery Markets 2018-2019 & Projections to 2028 - Routes of Drug Delivery, Formulations and Applications of Various Diseases

Retrieved on: 
Tuesday, February 5, 2019
Drug delivery, Medical equipment, Peptide

The cardiovascular drug delivery markets are estimated for the years 2018 to 2028 on the basis of epidemiology and total markets for cardiovascular therapeutics.

Key Points: 
  • The cardiovascular drug delivery markets are estimated for the years 2018 to 2028 on the basis of epidemiology and total markets for cardiovascular therapeutics.
  • Role of drug delivery in developing cardiovascular markets is defined and unmet needs in cardiovascular drug delivery technologies are identified.
  • Drug delivery to the cardiovascular system is approached at three levels: (1) routes of drug delivery; (2) formulations; and finally (3) applications to various diseases.
  • Formulations for drug delivery to the cardiovascular system range from controlled release preparations to delivery of proteins and peptides.